Roche is to return to antibiotic products after agreeing to take over an experimental drug being developed by closely-held Polyphor, in a deal that could be worth up to $548 million.
via WSJ.com: US Business http://online.wsj.com/article/SB10001424052702303936904579177651779970072.html?mod=pls_whats_news_us_business_f
via WSJ.com: US Business http://online.wsj.com/article/SB10001424052702303936904579177651779970072.html?mod=pls_whats_news_us_business_f
Nessun commento:
Posta un commento